A phylodynamic analysis of HIV-1 in Germany

Similar documents
Inter-country mixing in HIV transmission clusters: A pan-european phylodynamic study

WCPT COUNTRY PROFILE December 2017 SWEDEN

Smokefree Policies in Europe: Are we there yet?

WCPT COUNTRY PROFILE December 2017 HUNGARY

WCPT COUNTRY PROFILE December 2017 SERBIA

Overview of drug-induced deaths in Europe - What does the data tell us?

Who is a migrant? 12/10/2018. HIV and migrants. Heterogeneous groups of persons with different migration drivers

Monthly measles and rubella monitoring report

Cross Border Genetic Testing for Rare Diseases

LEBANON. WCPT COUNTRY PROFILE December 2018

PARALLELISM AND THE LEGITIMACY GAP 1. Appendix A. Country Information

DENMARK. WCPT COUNTRY PROFILE December 2018

Lymphogranuloma venereum

GERMANY. WCPT COUNTRY PROFILE December 2018

Yersiniosis SURVEILLANCE REPORT. Annual Epidemiological Report for Key facts. Methods. Epidemiology

Where we stand in EFORT

European Collaboration on Dementia. Luxembourg, 13 December 2006

Syphilis SURVEILLANCE REPORT. Annual Epidemiological Report for Key facts. Methods

Measles and rubella monitoring January 2015

Trichinellosis SURVEILLANCE REPORT. Annual Epidemiological Report for Key facts. Methods

Where do EU Contries set the limit for low risk drinking.

Monitoraggio delle epatiti virali in Europa

Drinking guidelines used in the context of early identification and brief interventions in Europe: overview of RARHA survey results

Tuberculosis Now! Jon S Friedland MA, FRCPE, FMedSci. Infectious Diseases & Immunity

Rheumatoid Arthritis Disease Burden and Access to Treatment

10/07/18. Dr. Otilia Mårdh, ECDC. No conflicts of interest.

Shigellosis SURVEILLANCE REPORT. Annual Epidemiological Report for Key facts. Methods

The cancer burden in the European Union and the European Region: the current situation and a way forward

Hepatitis A SURVEILLANCE REPORT. Annual Epidemiological Report for Key facts. Methods

ALCOHOL CONSUMPTION IN EUROPE; TRADITIONS, GENERATIONS, CULTURE AND POLICY

Outcome of proficiency test on EIA serology

Manuel Cardoso RARHA Executive Coordinator Public Health MD Senior Advisor Deputy General-Director of SICAD - Portugal

TEDDY. Teddy Network of Excellence. Annagrazia ALTAVILLA. Ph.D. Sciences Ethics LL.M. Health Law. diterranée

The health economic landscape of cancer in Europe

Biology Report. Is there a relationship between Countries' Human Development Index (HDI) level and the incidence of tuberculosis?

Engagement in language assessment / Regions of Europe

PRESS RELEASE ISSUED BY THE STATE UNIVERSITY OF NEW YORK AT ALBANY

Weekly influenza surveillance overview

Epidemiology of tuberculosis in Europe. Marieke J. van der Werf European Centre for Disease Prevention and Control Amsterdam, 22 September 2014

Project Meeting Prague

real-time AQ data 2007 and plans for 2008

REPORT FROM THE COMMISSION TO THE EUROPEAN PARLIAMENT, THE COUNCIL, THE EUROPEAN ECONOMIC AND SOCIAL COMMITTEE AND THE COMMITTEE OF THE REGIONS

ECDC and Spanish Ministry of Health workshop:

The Identification of Food Safety Priorities using the Delphi Technique

Alcohol-related harm in Europe and the WHO policy response

Q1 What age are you?

Molecular typing for surveillance of multidrug-resistant tuberculosis in the EU/EEA

Giardiasis (lambliasis)

Summary. Primary care data. Week 49/2014. Season

UK bowel cancer care outcomes: A comparison with Europe

Burden and cost of alcohol, tobacco and illegal drugs globally and in Europe

Media Release. Inaugural study reveals that more than one in four women in European and Central Asian prisons locked up for drug offences

Injecting trends in Austria including results of a systematic literature review on interventions aiming to influence the route of administration

Inequalities in health: challenges and opportunities in Europe Dr Zsuzsanna Jakab WHO Regional Director for Europe

Estimating Smoking Related Cause of Death: a Cohort Approach Based on Lung Cancer Mortality in six European Countries

The Risk of Alcohol in Europe. Bridging the Gap June 2004

A report on the epidemiology of selected vaccine-preventable diseases in the European Region 30% 20% 10%

European monthly measles monitoring (EMMO)

Table 7.1 Summary information for lung cancer in Ireland,

Table 9.1 Summary information for stomach cancer in Ireland,

Atherosclerotic Cardiovascular Diseases: ischaemic heart disease and stroke

National Institute on Alcohol Abuse and Alcoholism. Environmental Approaches

Multidrug- and extensively drug-resistant tuberculosis: a persistent problem in the European Union European Union and European Economic Area

11 Melanoma of the skin

Highly pathogenic avian influenza "The Epidemic" Regionalisation in the European Union

Finnish international trade 2017 Figures and diagrams. Finnish Customs Statistics

Is there a relationship between Countries' Human Development Index (HDI) level and the incidence of tuberculosis?

Emerging Risks Mapping of Activities in Member States. 67th Advisory Forum meeting, Utrecht, The Netherlands, 6 February 2018

Finnish international trade 2017 Figures and diagrams. Finnish Customs Statistics

Risk of HIV-1 low level viremia to treatment. Germany. Nadine Lübke Düsseldorf

Underage drinking in Europe

European Status report on Alcohol and Health

Highlighting in the WHO European Region: Summary. No. 21(February 2012)

Research paper: Legal treatment of the use of cannabis for medical purposes in the member states of the European Union

Men & Health Work. Difference can make a difference Steve Boorman & Ian Banks RSPH Academy 2013

Trends in injecting drug use in Europe

EUVAC.NET A surveillance network for vaccine-preventable diseases

Critical immunity thresholds for measles elimination

Invasive meningococcal disease

European Community Pharmacy: a reference in Public Health

Global Trade in Lightweight Coated Writing Paper TradeData International Pty Ltd ( Page 1 5/18/2015

Table 6.1 Summary information for colorectal cancer in Ireland,

SOITC Press Ad FAQs. Q: When will these Terms and Conditions changes come into effect?

Overall survival: 1 st line therapy

List of nationally authorised medicinal products

Nutrient profiles for foods bearing claims

EFSA s Concise European food consumption database. Davide Arcella Data Collection and Exposure Unit

31 countries (117 registries, 20 national) Increased coverage in countries with regional registries 50% European population Overall >20 million

Situation update in the European Region: overview of influenza surveillance data week 40/2009 to week 07/2010.

CEN/TC 264/WG 39. Ambient air Sampling and analysis of airborne pollen grains and mold spores of allergy networks Volumetric Hirst method

European status report on alcohol and health Leadership, awareness and commitment

Screening for Cervical Cancer in Europe

Ongoing HIV-1 subtype B transmission networks amongst MSM in the Netherlands. Daniela Bezemer. HIV Monitoring Foundation Amsterdam The Netherlands

Transcription:

A phylodynamic analysis of HIV-1 in Germany Prabhav Kalaghatgi Max Planck Institute for Informatics, Saarbrücken RKI workshop 2015, Berlin

Number of cases Incidence of HIV-1 in Western Europe Figure 2. Number of diagnosed HIV reported infections adjusted for reporting delay, by transmission mode, origin and year, EU/ EEA, 2006 2012 10000 9000 8000 7000 6000 5000 4000 3000 2000 1000 0 2006 2007 2008 2009 2010 2011 2012 Year of diagnosis Men who have sex with men Heterosexual cases, excluding cases from Sub- Saharan African countries Other/undetermined Heterosexual cases from sub- Saharan African countries Injecting drug use Mother-to-child transmission Source: Country reports from Austria, Belgium, Bulgaria, Croatia, Cyprus, Czech Republic, Denmark, Finland, France, Germany, Greece, Hungary, Iceland, Ireland, Latvia, Lithuania, Luxembourg, Malta, Netherlands, Norway, Portugal, Romania, Slovakia, Slovenia, Sweden and United Kingdom. ECDC. Annual epidemiological report 2014. Prabhav Kalaghatgi 2/14

Motivation HIV incidence is not reducing and the epidemic needs to be monitored. Prabhav Kalaghatgi 3/14

Motivation HIV incidence is not reducing and the epidemic needs to be monitored. Viruses sampled from patients sharing a transmission event are closely related. Prabhav Kalaghatgi 3/14

Motivation HIV incidence is not reducing and the epidemic needs to be monitored. Viruses sampled from patients sharing a transmission event are closely related. Viral sequence data collected from patients can help reconstruct transmission clusters. Prabhav Kalaghatgi 3/14

Patient data 2349 patients from Seroconverter cohort (SC) 5283 patients from RESINA cohort 2000 Patients Cohort RESINA SC 1000 0 HET IVDA MSM Other/Unknown factor(infectionroute) Prabhav Kalaghatgi 4/14

Sequence data 753 nt of pol gene sites under selection removed (WHO list) predominantly subtype B (COMET) 300 200 Patients Cohort RESINA SC 100 0 1995 2000 2005 2010 2015 Sampling date Prabhav Kalaghatgi 5/14

Identifying transmission clusters Set of individuals that are part of the same transmission chain. 1000 bootstrap phylogenetic trees using FastTree Clusters identified as follows: 1. Partition tree into clades at 90% support 2. Add edges between patients in same clade if seq. dist less than 0.03 sub/site 50 86 83 64 76 56 92 75 I K 45 56 73 29 100 43 91 J L N 11 89 25 28 29 42 52 F O M E 75 D P C Q R G S T B H A U 91 Z W 0.18 0.16 0.14 0.12 0.10 0.08 0.06 0.04 0.02 X V Y 0 Prosperi et al. Nat. Commun.; 2011 Prabhav Kalaghatgi 6/14

Cluster size distribution Number of clusters 0 100 200 300 400 500 2 5 8 11 16 20 25 30 36 53 Transmission cluster size Prabhav Kalaghatgi 7/14

Proportion of RESINA and SC patients in each cluster 60 40 Cluster size count 300 200 100 20 0 0.0 0.4 0.8 Proportion of patients from RESINA Prabhav Kalaghatgi 8/14

Clustering by infection route MSM HET IVDA Other/Unknown Prabhav Kalaghatgi 9/14

Characteristics of the five largest clusters Size Cohort Infection route Subtype 53 60% RESINA, 40%SC MSM B 37 86% RESINA, 13%SC MSM B 36 61% RESINA, 39%SC MSM B 30 83% RESINA, 17%SC IVDA B 27 22% RESINA, 78%SC MSM B Prabhav Kalaghatgi 10/14

Time-scaled tree for largest cluster (n = 53, MSM) inferred using BEAST RESINA SC 1995.0 2000.0 2005.0 2010.0 Time Prabhav Kalaghatgi 11/14

Time-scaled tree for largest cluster (n = 53, MSM) inferred using BEAST RESINA SC 1995.0 2000.0 2005.0 2010.0 Time Tree height Prabhav Kalaghatgi 11/14

Tree heights of the five largest transmission clusters Size Infection route Tree height (yr) Subtype 53 MSM 20 ± 2.42 B 37 MSM 15.2 ± 1.28 B 36 MSM 16.14 ± 2.52 B 30 IVDA 10.5 ± 2.83 B 27 MSM 15.35 ± 2.74 B Prabhav Kalaghatgi 12/14

Summary HIV-1 sequences from 7632 patients (SC, RESINA) were analyzed. Prabhav Kalaghatgi 13/14

Summary HIV-1 sequences from 7632 patients (SC, RESINA) were analyzed. 3327 (44%) patients were present in 956 transmission clusters. Prabhav Kalaghatgi 13/14

Summary HIV-1 sequences from 7632 patients (SC, RESINA) were analyzed. 3327 (44%) patients were present in 956 transmission clusters. 195 clusters contained patients (1140) from both SC and RESINA. Prabhav Kalaghatgi 13/14

Summary HIV-1 sequences from 7632 patients (SC, RESINA) were analyzed. 3327 (44%) patients were present in 956 transmission clusters. 195 clusters contained patients (1140) from both SC and RESINA. Analysis benefited from having data from both SC and RESINA. Prabhav Kalaghatgi 13/14

Summary HIV-1 sequences from 7632 patients (SC, RESINA) were analyzed. 3327 (44%) patients were present in 956 transmission clusters. 195 clusters contained patients (1140) from both SC and RESINA. Analysis benefited from having data from both SC and RESINA. Most large clusters were established over 15 years ago. Prabhav Kalaghatgi 13/14

Acknowledgements Universitätsklinikum Köln Elena Knops Eugen Schülter Rolf Kaiser RKI Claudia Kücherer Andrea Hauser Norbert Bannert Barbara Bartmeyer MPI Informatik Prabhav Kalaghatgi Nico Pfeifer Joachim Büch Thomas Lengauer Uniklinik Düsseldorf Björn Jensen Prabhav Kalaghatgi 14/14